- Open Access
miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level
- Shen-meng Gao†1,
- Chong-yun Xing†2,
- Chi-qi Chen1,
- Si-si Lin1,
- Pei-hong Dong3 and
- Fu-jun Yu3Email author
© Gao et al; licensee BioMed Central Ltd. 2011
Received: 9 September 2011
Accepted: 1 December 2011
Published: 1 December 2011
miR-15a and miR-16-1(miR-15a/16-1) have been implicated as tumor suppressors in chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemic cells. However the mechanism of inhibiting the proliferation of leukemic cells is poorly understood.
K562 and HL-60 cells were transfected with pRS-15/16 or pRS-E, cell growth were measured by CCK-8 assay and direct cell count. Meanwhile WT1 protein and mRNA level were measured by Western blotting and quantitative real-time PCR.
In this study we found that over-expression of miR-15a/16-1 significantly inhibited K562 and HL-60 cells proliferation. Enforced expression of miR-15a/16-1 in K562 and HL-60 cells significantly reduced the protein level of WT1 but not affected the mRNA level. However enforced expression of miR-15a/16-1 can not reduce the activity of a luciferase reporter carrying the 3'-untranslated region(3'UTR) of WT1. Silencing of WT1 by specific siRNA suppressed leukemic cells proliferation resembling that of miR-15a/16-1 over-expression. Anti-miR-15a/16-1 oligonucleotides (AMO) reversed the expression of WT1 in K562 and HL-60 cells. Finally, we found a significant inverse correlation between miR-15a or miR-16-1 expression and WT1 protein levels in primary acute myeloid leukemia (AML) blasts and normal controls.
These data suggest that miR-15a/16-1 may function as a tumor suppressor to regulate leukemic cell proliferation potentially by down-regulating the WT1 oncogene. However WT1 is not directly targeted by miR-15a/16-1 through miRNA-mRNA base pairing, therefore more study are required to understand the mechanism by which miR-15a/16-1 downregulate WT1.
MicroRNAs (miRNAs) are non-coding regulatory RNAs of 21 to 25 nucleotides and regulate most of basal progress such as cell proliferation, survival, apoptosis, and differentiation by triggering either translational repression or mRNA degradation[1–3]. Recently an increasing number of data have demonstrated that almost 50% of miRNAs are located at or close to fragile sites of regions. This regions are known to be amplified or deleted in human cancer. miRNAs may function as tumor suppressor genes or potential oncogenes during the initiation and progression of cancer. The function of some miRNAs is dependent upon the specific cell type. On one hand miR-221 and miR-222 act as oncogenes in solid tumors, on the other hand the same miRNAs function as tumor suppressors in erythroblastic leukemia cells. In animals, single-stranded miRNA binds specific mRNA through sequences that are imperfectly complementary to the target mRNA, mainly to the 3' untranslated region (UTR). The bound mRNA can be degraded, resulting in decreased level of the corresponding mRNA or remains untranslated, resulting in decreased level of the corresponding protein[1, 7].
The miR-15a and miR-16-1 (miR-15a/16-1) cluster reside at a genomic region of chromosome 13q14.3, which frequently was deleted or down-regulated in the majority of chronic lymphocytic leukemia (CLL), and in a subset of mantle cell lymphomas. Calin et al. demonstrated that in MEG-01 cells enforced expression of miR-15a/16-1 inhibited cell proliferation and induce apoptosis through targeting multiple oncogenes such as Bcl-2, WNT3A, MCL1, and CCND1 in vitro and in vivo [9, 10]. However the mechanism of inhibiting the proliferation of leukemic cells is still not clear.
The Wilms' tumor gene (WT1) locating at the short arm of chromosome 11 regulates the expression of different genes like transforming growth factor beta, Bcl-2, and human telomerase reverse transcriptase[11–13]. High levels of WT1 which are detected in most cases of acute myelogeous leukemia and chronic myelogeous leukemia (CML) in blast crisis are associated with a worse long-time prognosis. WT1 is firstly thought to function as tumor suppressor, but the following wildly studies support that WT1 act as oncogene.
In this study we reported that miR-15a/16-1 were able to significantly suppress K562 and HL-60 cells proliferation through down-regulating WT1 protein level. Either down-regulation of WT1 by siRNA significantly inhibited the proliferation of leukemic cells. Thus, these data suggest that miR-15a/16-1 may function as a tumor suppressor to influence the proliferation of leukemic cells through down-regulating WT1 protein level. However, enforced expression of miR-15a/16-1 can not reduce the activity of a luciferase reporter carrying the 3'-untranslated region (3'UTR) of WT1. This result means that miR-15a/16-1 down-regulated the expression of WT1 not through miRNA-mRNA base pairing. Whether miR-15a/16-1 downregulate other genes which interact with WT1 is not decided. Therefore more study are required to shed light of the new mechanism, which will open new avenues in understanding the mechanisms of miRNA action.
Materials and methods
cell lines and primary leukemic cells
K562 and HL-60 cell lines were employed for the present study. All cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (Invitrogen, Groud Island, USA) in humidified 37°C incubator with 5% CO2. Primary AML cells were obtained from 20 patients with AML (2 M1 5 M2, 5 M3, 2 M4, 6 M5, the First Affiliated Hospital of Wenzhou Medical College). None of these patients had received any treatment. The diagnosis was established according to French-American-British classification. All patients gave informed consent in accordance with the Declaration of Helsinki for cryopreservation and use of the samples for molecular studies.
Bone marrow mononuclear cells from normal individuals and patients with AML were aspirated by Ficoll density gradient centrifugation (GE Healthcare, Uppsala, Sweden). Total RNA from cultured cell lines and bone marrow mononuclear cells were extracted by TRIzol (Invitrogen) Following the manufacture's protocol. RNA concentrations and quality were determined with Beckman DU6400 spectrophotometer (Beckman, USA) and gel analysis.
qPCR for miRNA and mRNA expression
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis for miR-15a and miR-16-1 was performed in triplicate with the NCode™ miRNA First-strand cDNA synthesis and SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. U6 snRNAs was used as the internal control. The fold-change for miR-15a/16-1 expression levels was calculated using ΔCT and 2-ΔΔCT. WT1 transcript was determined by quantitative real-time PCR using specific primer sets and ABL housekeeping gene was used for normalization. The following primers were used respectively, WT1: (sense strand: 5'-CAG GCT GCA ATA AGA GAT ATT TTA AG CT-3', antisense strand: 5'-GAA GTC ACA CTG GTA TGG TTT CTC A-3', Taqman probe: 5'-Fam-CTT ACA GAT GCA CAG CAG GAA GCA CAC TGA-Tamra-3'), ABL: (sense strand: 5'-GAT GTA GTT GCT TGG GAC CCA-3', antisense strand: 5'-TGG AGA TAA CAC TCT AAG CAT AAC TAA AGG T-3', Taqman probe: 5'-Fam-CCA TTT TTG GTT TGG GCT TCA CAC CAT T-Tamra-3').
pRETROSUPER vector expressing miR-15a/16-1 (pRS-15/16) was constructed as previously described [10, 18]. The same empty plasmid (pRS-E) was served as control. Leukemic cells were transiently transfected with 1 μg/mL (final concentration) pRS-E or pRS-15/16 vector using Lipofectamine™ LTX and PLUS™ Reagents (Invitrogen) according to the manufacturer's instructions.
Cell counting kit-8 (CCK-8) assay and trypan-blue exclusion assay
The mock or transfected K562, HL-60 and U937 cells were seeded into 96-well plates (6.0 × 103 cells/well). Cell viability was assessed by CCK-8 assay (Dojin Laboratories, Kumamoto, Japan). The absorbance at 450 nm (A450) of each well was read on a spectrophotometer. Three independent experiments were performed in quadruplicate. Alternatively, cell viability was determined by the trypan-blue exclusion assay, and growth inhibition rate was calculated according to viable cell numbers of treated cells against numbers of untransfected cells.
siRNA and anti-miR-15a/16-1 oligonucleotide (AMO) transfection
SiRNA sequences targeting WT1 (National Center for Biotechnology Information accession number AH003034) were synthesized. siRNA-WT1: ccauaccagugugacuuca corresponds to positions 9-27 of exon 7 within the WT1 coding sequence. SiRNA-WT1 and unspecific control siRNA (N.C) were obtained from Invitrogen. SiRNA-WT1 and N.C were transfected into K562 and HL-60 cells by the aid of Hiperfect transfection reagent (Qiagen, Valencia, USA). The sequences of anti-miR-15a/16-1 oligonucleotide (AMO) were designed according to the principle of sequences complementary to mature miR-15a and miR-16-1. AMO and scramble (SCR) were chemically synthesized by Qiagen. AMO and SCR (final concentration of 50 nM) were transfected into K562 and HL-60 cells mediated by Hiperfect transfection reagent (Qiagen).
Bone marrow mononuclear cells from normal individuals and patients with AML were aspirated by Ficoll density gradient centrifugation (GE Healthcare). Protein extracts from cell lines, normal individuals and patient samples prepared with RIPA lysis buffer (50 mM TrisHCl, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodiumdeoxycholate, 1 mM PMSF, 100 mM leupeptin, and 2 mg/mL aprotinin, pH 8.0) were separated on an 8% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. After blocking with 5% nonfat milk, the membranes were incubated with an appropriate dilution (WT1 1:2000) of the primary antibody (Abcom, Cambridge, MA, USA), followed by incubation with the horseradish peroxidase(HRP)-conjugated secondary antibody (abcom) according to manufacturer's instructions. The signals were detected by chemiluminescence phototope-HRP kit (Cell Signaling, Danvers, MA, USA) according to manufacturer's instructions. As necessary, blots were stripped and reprobed with anti-GAPDH antibody (Abcom) as an internal control. All experiments were repeated three times with the similar results. Signal intensity of proteins was normalized against GAPDH using Quantity One (Bio-Rad).
Luciferase reporter experiments
The 3'UTR segments from the WT1 and Bcl-2 gene were amplified by PCR from cDNA and inserted into the pGL3 control vector (Promega), using the XbaΙ site immediately downstream from the stop codon of luciferase. Bcl-2 is one of known targeted gene by miR-15a/16-1. The following primer set was used to generate specific fragments: Bcl-2UTRF, 5'-CTA GTC TAG AGC CTC AGG GAA CAG AAT GAT CAG-3'; Bcl-2UTRR, 5'-CTA GTC TAG AAA GCG TCC ACG TTC TTC ATT G-3'. WT1UTRF, 5'-CTA GTC TAG GTA GAC CCA AAG GTC CTT AAG TT-3'; WT1UTRR, 5'-CTA GTC TAG GAT ACC GGT GCT TCT GGA A-3'. The cells were cotransfected in 24 well plate using Lipofectamine™ LTX and PLUS™ Reagents (Invitrogen) according to the manufacturer's protocol using 0.1 ug of the firefly luciferase report vector and 0.1 ug of the control vector pRL-TK (Promega, WI, USA) containing Renilla luciferase. For each well 0.5 ug pRS-15/16 or negative control pRS-E were used. Firefly and Renilla luciferase activities were measured by dual luciferase reporter assay (Promega) after transfection. Firefly luciferase activity was normalized to Renilla luciferase activity.
The significance of the difference between groups was determined by Student's t-test. A P value of less than .05 was considered statistically significant. Relationships between miR-15a/16-1 and WT1 expression were explored by Pearson's correlation coefficient. All statistical analyses were performed with SPSS software (version 13).
miR-15a/16-1 suppress the proliferation of K562 and HL-60 cells
miR-15a/16-1 reduce WT1 protein level not through targeting mRNAs according to the degree of complementarity with their 3'UTR
Anti-miR-15a/16-1 oligonucleotides (AMO) reversed the expression of WT1 in K562 and HL-60 cells
WT1 is involved in the regulation of cell proliferation by miR-15a/16-1
The levels of miR-15a/16-1 are inversely correlated with WT1 protein expression in leukemic cells
Although miRNA signatures for leukemic cell have been established, elucidation of the role of miRNAs in leukemogenesis remains in the early stage of development. Calin and others presented that miR-15a/16-1 act as tumor suppressor by inhibiting the growth of tumor engraftments of leukemic cells in nude mice in vivo. Furthermore using microarray and proteomics analysis, they found miR-15a/16-1 exerted antileukemic effect by targeting Bcl-2, WT1, and PDCD4 . We used PicTar, TargetScan, and MiRanda, the most widely used algorithms for the identification of miRNA targets, to predict the target of miR-15a/16-1. To our surprise we could not find WT1 as the predicted target of miR-15a/16-1. Then we cloned the 3'UTR region of WT1 downstream of a luciferase reporter gene and corresponding negative control into K562 and HL-60 cells, but the luciferase activity of cells transfected with pRS-15/16 was not significantly decreased compared with the negative control. This data indicate miR-15a/16-1 regulate WT1 protein expression not through targeting mRNAs according to the degree of complementarity with their 3'UTR. miR-15a/16-1 might regulate gene transcription by a different mechanism than RNA-induced silencing complex mediated protein translation inhibition and/or mRNA cleavage.
Our understanding of the mechanisms by which miRNAs mediate their effects probably reflects a tip of the iceberg. Eiring et al. demonstrated that the interaction between miR-328 and poly(rC)-binding protein hnRNP E2 is independent of the microRNA's seed sequence. They also revealed the dual ability of a microRNA to control cell fate not only through base pairing with mRNA targets but also through a decoy activity that interferes with the function of regulatory proteins. miRNAs also target the 5'UTR or the coding sequence of mRNA and contribute to their down-regulation. Jing et al. showed that AU-rich elements (AREs) mediated instability was implicated in the regulation of gene expression by miR-15a and miR-16-1. Given that the interaction of miRNAs and their target genes is complicated, more research is needed to decipher the mechanisms by which miR-15a/16-1 down-regulate WT1 protein level.
miR-15a/16-1 probably regulated the expression of WT1 through an indirect effect on WT1. Several transcription factors including GATA-1 and Sp1, which bind to DNA consensus site at the proximal promoter of the WT1 gene, can regulate the expression of WT1[24, 25]. We speculated whether GATA-1 and Sp1 were the targets of miR-15a/16-1. We used PicTar, TargetScan, and MiRanda to predict whether GATA-1 and Sp1 were the targets of miR-15a/16-1. However we could not find GATA-1 and Sp1 as the predicted targets of miR-15a/16-1. Meanwhile GATA-1 and Sp1 protein levels were not decreased by Western blotting after K562 cell was transfected by miR-15a/16-1 (data not shown). These data show that GATA-1 and Sp1 are not the targets of miR-15a/16-1. Considering that many transcription factors could regulate the expression of WT1, more study are required to test the possibility that WT1 was regulated by downstream targets of miR-15a/16-1.
Overexpression of WT1 is known to modulate apoptosis by upregulation of Bcl-2 gene expression[12, 26]. However Hewitt et al. founded that WT1 could suppress the Bcl-2 promoter in transient transfection assays. Murata et al. did not see significant changes in Bcl-2 expression in the M1 cells which induced to express WT1 (+Ex5/-KTS). These conflicting data demonstrate that the function of WT1 is cell-type specific. Depending on the cell type being investigated, WT1 can either activate Bcl-2 and function as an oncogene or suppress Bcl-2 and function as a tumor suppressor. Although Bcl-2 is a known direct target by miR-15a/16-1, whether miR-15a/16-1 indirectly down-regulate Bcl-2 expression through WT1 mediated down-regulation of Bcl-2 is still not proved in lab.
Depending on the cell type, WT1 had either tumor-promoting or tumor-suppressing function[29, 30]. Overexpression of WT1 in human prostate cancer cells inhibited proliferation, but the expression of WT1 in leukemic cells enhanced proliferation[31, 32]. Furthermore in AML and chronic myeloid leukemia (CML) patients high level of WT1 was associated with a worse long time outcome and poor event-free survival[14, 33]. Yamagami et al. demonstrated that loss of WT1 was associated with decreased growth of the leukemic cells and rapid induction of apoptosis, when endogenous WT1 in highly expressing leukemic cell lines and primary AML samples was decreased by antisense oligonucleotides and RNA interference[34, 35]. Our data showed down-regulation of WT1 by either miR-15a/16-1 over-expression and specific siRNA significantly inhibited the proliferation of leukemic cells. This data suggest that WT1 plays an important role in leukemogenesis. As WT1 is ordinary over-expressing in AML and CML patients, targeting WT1 as possible tool against leukemic cells provides a new therapeutic option for AML and CML patients. The use of miR-15a/16-1 or siRNA against WT1 will have an effect in CML patients because suppressing of WT1 expression in vitro was associated with inhibition of BCR-ABL tyrosine kinase activity.
Our data demonstrated for the first time that over-expression of miR-15a/16-1 significantly inhibited K562 and HL-60 cells proliferation through down-regulating WT1 protein level. However miR-15a/16-1 down-regulated WT1 protein level not through targeting mRNAs according to the degree of complementarity with their 3'UTR. The most important thing is to shed light on the new mechanisms by which miRNA mediated their effect, which will open new avenues for miRNA action.
The project supported by National Natural Science Foundation of China (81000176/H0317), Zhejiang Provincial Natural Science Foundation of China (Y2090326, 2110634), Scientifical Research Foundation (Y201119952) of Zhejiang Provincial Education Department, Wang Bao-En liver fibrosis foundation No 20100002.
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.View ArticlePubMedGoogle Scholar
- Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, Calin GA, Liu CG, Andreeff M, Croce CM: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene. 2007, 26: 4148-4157. 10.1038/sj.onc.1210186.View ArticlePubMedGoogle Scholar
- Ventura A, Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell. 2009, 136: 586-591. 10.1016/j.cell.2009.02.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004, 101: 2999-3004. 10.1073/pnas.0307323101.PubMed CentralView ArticlePubMedGoogle Scholar
- Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6: 857-866. 10.1038/nrc1997.View ArticlePubMedGoogle Scholar
- Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009, 10: 704-714. 10.1038/nrg2634.PubMed CentralView ArticlePubMedGoogle Scholar
- Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005, 433: 769-773. 10.1038/nature03315.View ArticlePubMedGoogle Scholar
- Navarro A, Bea S, Fernandez V, Prieto M, Salaverria I, Jares P, Hartmann E, Mozos A, Lopez-Guillermo A, Villamor N, Colomer D, Puig X, Ott G, Sole F, Serrano S, Rosenwald A, Campo E, Hernandez L: MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res. 2009, 69: 7071-7078. 10.1158/0008-5472.CAN-09-1095.View ArticlePubMedGoogle Scholar
- Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005, 102: 13944-13949. 10.1073/pnas.0506654102.PubMed CentralView ArticlePubMedGoogle Scholar
- Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM: MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA. 2008, 105: 5166-5171. 10.1073/pnas.0800121105.PubMed CentralView ArticlePubMedGoogle Scholar
- Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ, Kim SJ: Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol. 1994, 8: 595-602. 10.1210/me.8.5.595.PubMedGoogle Scholar
- Loeb DM: WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. Cell Cycle. 2006, 5: 1249-1253. 10.4161/cc.5.12.2807.View ArticlePubMedGoogle Scholar
- Oh S, Song Y, Yim J, Kim TK: The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem. 1999, 274: 37473-37478. 10.1074/jbc.274.52.37473.View ArticlePubMedGoogle Scholar
- Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D: High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997, 90: 1217-1225.PubMedGoogle Scholar
- Morrison AA, Viney RL, Ladomery MR: The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta. 2008, 1785: 55-62.PubMedGoogle Scholar
- Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M, Lo Coco F, Saglio G: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002, 16: 2115-2121. 10.1038/sj.leu.2402675.View ArticlePubMedGoogle Scholar
- Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003, 17: 2474-2486. 10.1038/sj.leu.2403136.View ArticlePubMedGoogle Scholar
- Gao SM, Chen C, Wu J, Tan Y, Yu K, Xing CY, Ye A, Yin L, Jiang L: Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. Biochem Biophys Res Commun. 2010, 403: 203-208. 10.1016/j.bbrc.2010.10.137.View ArticlePubMedGoogle Scholar
- Glienke W, Maute L, Koehl U, Esser R, Milz E, Bergmann L: Effective treatment of leukemic cell lines with wt1 siRNA. Leukemia. 2007, 21: 2164-2170. 10.1038/sj.leu.2404878.View ArticlePubMedGoogle Scholar
- Lawrie CH: MicroRNAs and haematology: small molecules, big function. Br J Haematol. 2007, 137: 503-512. 10.1111/j.1365-2141.2007.06611.x.View ArticlePubMedGoogle Scholar
- Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140: 652-665.Google Scholar
- Calin GA, Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006, 66: 7390-7394. 10.1158/0008-5472.CAN-06-0800.View ArticlePubMedGoogle Scholar
- Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J: Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell. 2005, 120: 623-634. 10.1016/j.cell.2004.12.038.View ArticlePubMedGoogle Scholar
- Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S, Kikuchi R, Iwasaki T, Takagi A, Kojima T, Suzuki M, Abe A, Naoe T, Murate T: GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Leukemia. 2009, 23: 1270-1277. 10.1038/leu.2009.13.View ArticlePubMedGoogle Scholar
- Cohen HT, Bossone SA, Zhu G, McDonald GA, Sukhatme VP: Sp1 is a critical regulator of the Wilms' tumor-1 gene. J Biol Chem. 1997, 272: 2901-2913. 10.1074/jbc.272.5.2901.View ArticlePubMedGoogle Scholar
- Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, Baldwin AS: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J. 1999, 18: 3990-4003. 10.1093/emboj/18.14.3990.PubMed CentralView ArticlePubMedGoogle Scholar
- Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ, Saunders GF: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res. 1995, 55: 5386-5389.PubMedGoogle Scholar
- Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T: The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett. 1997, 409: 41-45. 10.1016/S0014-5793(97)00477-8.View ArticlePubMedGoogle Scholar
- Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, Sugiyama H: AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2006, 107: 3303-3312. 10.1182/blood-2005-04-1656.View ArticlePubMedGoogle Scholar
- Morrison DJ, English MA, Licht JD: WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res. 2005, 65: 8174-8182. 10.1158/0008-5472.CAN-04-3657.View ArticlePubMedGoogle Scholar
- Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M: Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene. Int J Oncol. 2004, 24: 461-471.PubMedGoogle Scholar
- Kerst G, Bergold N, Viebahn S, Gieseke F, Kalinova M, Trka J, Handgretinger R, Muller I: WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase. Leuk Res. 2008, 32: 1393-1399. 10.1016/j.leukres.2008.03.006.View ArticlePubMedGoogle Scholar
- Jacobsohn DA, Tse WT, Chaleff S, Rademaker A, Duerst R, Olszewski M, Huang W, Chou PM, Kletzel M: High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol. 2009, 146: 669-674. 10.1111/j.1365-2141.2009.07770.x.View ArticlePubMedGoogle Scholar
- Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996, 87: 2878-2884.PubMedGoogle Scholar
- Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, Asada M, Jomgeow T, Aoyagi S, Nakano Y, Tamaki H, Sakaguchi N, Shirakata T, Nishida S, Kawakami M, Tsuboi A, Oka Y, Tsujimoto Y, Sugiyama H: Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene. 2006, 25: 4217-4229. 10.1038/sj.onc.1209455.View ArticlePubMedGoogle Scholar
- Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004, 101: 979-988. 10.1002/cncr.20457.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.